HRAS and renal carcinoma: For example, tipifarnib is a farnesyltransferase inhibitor targeting HRAS that increases anti-cancer effects through the prevention of apoptosis of T cells and downregulation of the level of cellular PD-L1 of renal cancer cells [40].